VIP (Vasoactive Intestinal Peptide)

VIP is a 28-amino-acid neuropeptide produced by neurons throughout the central and peripheral nervous systems and by enteric and immune cells. It binds VPAC1 and VPAC2 receptors, both G-protein-coupled receptors with broad tissue distribution.

VIP was first isolated from porcine intestine by Sami Said and Viktor Mutt in 1970. Its initial characterization as a vasodilator gave it its name; subsequent decades of research established its broad role as a neuropeptide signaling across the immune, nervous, and respiratory systems. VIP is structurally related to PACAP and the secretin / glucagon family of peptides.

VIP has anti-inflammatory effects on multiple immune cell types — reducing pro-inflammatory cytokine production, modulating T-cell differentiation toward regulatory phenotypes, and dampening macrophage activation. Its receptors are expressed in airway smooth muscle, immune cells, neurons, and gastrointestinal tissue.^[1]

VIP has a notably short plasma half-life (a few minutes), reflecting its biology as a paracrine and neurocrine signaling molecule rather than a circulating hormone. Therapeutic strategies have focused on aerosol delivery (for pulmonary indications), engineered analogs with extended half-life, and receptor-selective agonists.

The peer-reviewed literature on VIP is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

Most published research used inhaled or intravenous VIP. Compounded intranasal VIP is sometimes used in chronic-illness communities; this is off-label and outside formal clinical trials.

VIP is a foundational neuropeptide of human physiology — substantially more biologically substantive than most peptides in the modern wellness ecosystem. The endogenous biology covers gut motility, immune tolerance, pulmonary vasodilation, and circadian rhythm; the disease-relevant mechanisms in inflammation and respiratory biology are well-characterized. The honest framing on translational evidence: the 471-patient ZYESAMI Phase 3 in COVID ARDS is the largest formal VIP-mechanism human trial and produced signals without leading to approval. The CIRS, long-COVID, and chronic-illness community use that drives most current research-peptide interest in VIP has outrun the controlled human evidence in those specific populations.

VIP appears in the Gut Healing & Mucosal Barrier Stack as a complementary anti-inflammatory partner to KPV, BPC-157, and other gut-focused peptides. For users in CIRS or chronic-illness contexts, intranasal compounded VIP under qualified-practitioner supervision is the established off-label use pattern — meaningful biology with thin controlled human evidence in those specific populations, accessed through compounding pharmacy channels rather than approved drug supply.